Levetiracetamum Eugia (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which modulates neurotransmitter release. This action stabilises neuronal firing and reduces hyper‑excitability, thereby decreasing the likelihood of seizure generation and spread.

The appropriate dose is determined by the prescribing clinician based on the patient’s age, weight, renal function, and seizure type. Dosing is individualized and should follow the prescriber’s instructions and local guidelines.

Safety data for levetiracetam during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Levetiracetam has a distinct mechanism (SV2A modulation) and a relatively favourable interaction profile compared with many enzyme‑inducing agents such as carbamazepine or phenytoin. It is often chosen for patients who need a medication with minimal hepatic metabolism and fewer drug‑drug interactions, though individual response and tolerability vary.

The product should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use and discard any solution that appears discoloured or contains particles.

Levetiracetamum Eugia is supplied as a sterile injection solution for intravenous infusion. It should be administered by a qualified healthcare professional, typically diluted in compatible IV fluids and infused over a period recommended by the prescriber.

Serious adverse events include severe allergic reactions (e.g., anaphylaxis or Stevens‑Johnson syndrome), marked mood or behavior changes such as depression or suicidal thoughts, and hematologic abnormalities like low blood cell counts. Prompt medical attention is required if any of these occur.

Patients with a known hypersensitivity to levetiracetam or any component of the injection solution should avoid its use. Caution is also advised for individuals with severe renal impairment, as dose adjustment may be necessary, and for those with a history of serious psychiatric disorders.